3,4-di-t-butylpyrrole | 22808-04-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 3,4-di-t-butylpyrrole
• 英文别名: 3,4-ditert-butyl-1H-pyrrole
• CAS: 22808-04-4
• 化学式: C₁₂H₂₁N
• 分子量: 179.305
• InChiKey: OLUVJEYXNKRHRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  1-(p-tolylsulfonyl)-3,4-di-tert-butylpyrrole 在 alkali 作用下， 以 甲醇 、 水 为溶剂， 以93%的产率得到3,4-di-t-butylpyrrole
  参考文献：
  名称：

  Synthesis and characterization of 3,4-dl-t-butylfuran, pyrrole, and selenophene

  摘要：

  DOI：

  10.1016/s0040-4039(00)97652-4

文献信息

• HEPATITIS B ANTIVIRAL AGENTS
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20160289212A1

  公开（公告）日：2016-10-06

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-L-R 1 (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药： X-A-Y-Z-L-R 1 （I） 这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• AZAINDOLE INHIBITORS OF AURORA KINASES
  申请人：DHANAK Dashyant

  公开号：US20070149561A1

  公开（公告）日：2007-06-28

  The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including solid tumor cancers and hematological cancers.

  本发明涉及一种由化学式（I）表示的化合物： 及其药学上可接受的盐。本发明的化合物抑制极化激酶，使其特别适用于治疗多种疾病，包括实体肿瘤癌和血液系统癌症。
• PROCESS FOR THE PREPARATION OF BENZOTRIAZEPINE DERIVATIVES
  申请人：Abdel-Magid F. Ahmed

  公开号：US20070066819A1

  公开（公告）日：2007-03-22

  The present invention is directed to a novel process for the preparation of benzo[e][1,2,4]triazepin-2-one derivatives, useful in the preparation of gastrin and cholecystokinin receptor ligands.

  本发明涉及一种新型制备苯并[e][1,2,4]三唑啶-2-酮衍生物的方法，该方法在胃泌素和胆囊收缩素受体配体的制备中具有用途。
• METHODS FOR THE CONVERSION OF A SUBSTITUTED FURAN TO A SUBSTITUTED PYRROLE
  申请人：Kreischer Bruce E.

  公开号：US20120083609A1

  公开（公告）日：2012-04-05

  The present invention discloses processes for producing substituted pyrrole compounds, such as 2,5-disubstituted pyrroles. Synthetic processes which directly convert substituted furan compounds to substituted pyrrole compounds, via a reaction of the substituted furan compound with ammonia and/or an ammonium salt in the presence of a catalyst, also are described.

  本发明揭示了生产取代吡咯化合物的过程，例如2,5-二取代吡咯化合物。还描述了一种合成过程，该过程通过将取代呋喃化合物与氨和/或铵盐在催化剂存在下反应，直接转化为取代吡咯化合物。
• Bicyclic And Tricyclic Compounds As KAT II Inhibitors
  申请人：Claffey Michelle M.

  公开号：US20100324043A1

  公开（公告）日：2010-12-23

  Compounds of Formula X: wherein A, X, Y, Z, R 5 , R 6a , and R 6b are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.

  化合物X的结构如下：其中A、X、Y、Z、R5、R6a和R6b的定义如本文所述，并且其药用盐被描述为用于治疗与精神分裂症及其他哺乳动物，包括人类，相关的认知缺陷的化合物，以及其他神经退行性和/或神经系统疾病。